Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Trial Profile

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 19 Jun 2018 Number of treatment arm has been changed from 3 to 4. Extended Treatment Arm IV arm has been added into the treatment.
    • 19 Jun 2018 Planned number of patients changed from 32 to 66.
    • 19 Jun 2018 Planned End Date changed from 30 Sep 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top